RO9021

RO9021 is a potent, selective, and orally bioavailable small molecule inhibitor of spleen tyrosine kinase (SYK). It acts as an ATP-competitive inhibitor, blocking the intracellular signaling pathways triggered by B-cell receptors (BCR) and Fc receptors, which are essential for the development and function of lymphoid cells. By inhibiting SYK, RO9021 suppresses BCR signaling in B cells, FcγR signaling in monocytes, and FcϵR signaling in mast cells, and it has been shown to inhibit osteoclastogenesis. The compound has been investigated for its potential in treating autoimmune and inflammatory disorders, such as rheumatoid arthritis and multiple sclerosis. Additionally, RO9021 has demonstrated antiproliferative and proapoptotic effects in acute myeloid leukemia (AML) cells and has been identified as a potential inhibitor of the mycobacterial serine/threonine protein kinase G (PknG), suggesting a role in tuberculosis research.

Other names

6-[(1R,2S)-2-amino-cyclohexylamino]-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amideCHEMBL3237561CHEMBL-3237561CHEMBL 3237561